---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-049967"
form_type: "8-K"
ticker: "OSRH"
cik: "0001840425"
company_name: "OSR Holdings, Inc."
filed_at: "2026-04-30T23:59:59+00:00"
generated_at: "2026-05-15T01:05:32.017386+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# OSR Holdings signs $815M VXM01 license with BCM Europe; largest shareholder pledges entire stake as collateral

## Summary
- Up to $815M in milestone payments from BCM Europe for VXM01 oral immunotherapy platform (Phase 3-ready VEGFR-2 target).
- BCM Europe pledges its entire 9,974,728 shares (~29.7% of OSRH) as collateral for milestone obligations; pledge effective Feb 2028.
- OSRH to acquire full VXM01 IP from Vaximm AG for $30M via separate asset purchase agreement.
- OSRH receives $15M equity put option at $10/share, exercisable after six months post-effective date.
- All downstream royalties after BCME recovers investment and preferred return flow to OSRH.

## SEC filing metadata
- accession: 0001213900-26-049967
- form_type: 8-K
- ticker: OSRH
- cik: 0001840425
- company_name: OSR Holdings, Inc.
- filed_at: 2026-04-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840425/000121390026049967/0001213900-26-049967-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840425/000121390026049967/ea0288465-8k_osrhold.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-049967
- JSON: https://secwatch.observer/filing/0001213900-26-049967.json
- Plain text: https://secwatch.observer/filing/0001213900-26-049967.txt

## Source-grounded claims
- claim_id: 90de46d6f5719e4999c930c75ce8e6e3e50c020d
  claim: OSR Holdings, Inc. entered into License Agreement with BCM Europe AG valued at up to $815,000,000 (effective 2026-04-29).
  evidence_excerpt: Global Exclusive License Agreement On April 29, 2026, OSR Holdings, Inc. (the “Company”), together with its wholly-owned subsidiary Vaximm AG (“Vaximm”), entered into a Global Exclusive License Agreement (the “License
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840425/000121390026049967/0001213900-26-049967-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.